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In a recent paper, Hamburger et al.1 outline a potential
mechanism for the pain and swelling that sometimes occurs
following intra-articular injections of hylan G-F 20
(Synvisc) for treating osteoarthritis pain of the knee. The
authors also describe an experimental approach to support
their thesis of an immunological candidate for these re-
sponses. We would like to point out (1) signiﬁcant inconsis-
tencies in their paper as compared to publicly available
information pertaining to the nature of adverse events re-
ported for viscosupplements, and (2) the lack of clear scien-
tiﬁc evidence from their study for supporting their proposed
mechanism.
The authors clearly indicate their bias that reactions in-
volving signiﬁcant pain and swelling to viscosupplements
for treating osteoarthritis pain of the knee only occur with
hylan G-F 20. They state that these types of reactions typ-
ically occur only after more than one injection, which they
believe suggests an immunological component to these re-
sponses that is unique to hylan G-F 20. It is important to
point out that all hylauronate (HA) based preparations orig-
inate from non-human sources, either avian or bacterial.
These highly puriﬁed preparations have protein levels typi-
cally in the ppm range, however, even a small amount of
protein can be immunogenic in the rare individual. Even
though the presence of an immunogenic response does
not necessarily have a clinical correlate, all HA based prod-
ucts have a contraindication for patients with known hyper-
sensitivity to the speciﬁc material source. Further, another
Food and Drug Administration (FDA) approved hyaluronate
viscosupplement has a warning on its label stating; ‘‘Ana-
phylactoid and allergic reactions have been reported.’’2,
which is absent from the hylan G-F 20 label. However,
a reading of the Hamburger et al. article would give a mis-
leading impression that other viscosupplements are not ca-
pable of generating an immunogenic response. As
anaphylaxis is a systemic response, what about local reac-
tions of signiﬁcant pain and swelling following intra-articular
hyaluronate injections? Do these occur with both cross-
linked HA (hylan G-F 20) and non-crosslinked HA
viscosupplements?
After examining the publicly available information for non-
crosslinked and crosslinked HA based preparations in the
FDA MAUDE database, and in contrast to Hamburger
et al., the answer is clearly yes3. These types of rare local
reactions can occur, and have been reported, with
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This includes pain and swelling after more than one injec-
tion, a response that, based on the FDA MAUDE database,
Hamburger et al. incorrectly imply does not occur with non-
crosslinked sodium hyaluronate products. One of the Hyal-
gan cases is described as ‘‘a ‘septic-like’ left knee after
second or third injection.’’ The patient was given a course
of ﬁve injections in the right knee without incident, and had
the reaction after the second or third injection in the left knee.
The authors also reference a paper by Puttick et al.4 as
further evidence to the potential immunological response
in patients experiencing pain and swelling following injec-
tion. Hamburger et al. state that Puttick et al. ‘‘found chick-
en-protein reactive antibodies in serum from a patient’’ with
an episode of pain and swelling following hylan G-F 20 in-
jection. A more thorough reading of this paper reveals that
this patient may have had antibodies to chicken protein,
but they did not have antibodies to hylan G-F 20. In contrast
to Hamburger et al., Puttick et al. correctly state that the sig-
niﬁcance of the reaction to chicken protein in this patient ‘‘is
unclear in the absence of control data’’ (i.e., analysis of sera
prior to injection). Interestingly overlooked by Hamburger
et al. in the Puttick reference is that an additional hylan
G-F 20 injection, in four of ﬁve patients that had an initial re-
action, did not result in a subsequent reaction pointing away
from an immunologic component to the initial response in
these patients.
The next question is whether the Hamburger et al. study
conﬁrms ‘‘the presence of a speciﬁc immunogenic protein
species in hylan G-F 20.’’. The study described by Ham-
burger et al. is methodologically inadequate to support an
unambiguous identiﬁcation of a hylan G-F 20 speciﬁc immu-
nogenic protein species. In particular: (1) there is no infor-
mation provided by the authors as to the number of
animals in this study, the number of animals in each study
group, and the number of animals in the ‘‘pools of SYN im-
munized rabbits.’’. The last one implies the addition to-
gether of sera from more than one animal that had ‘‘high’’,
‘‘medium’’, or ‘‘low’’ optical density (OD) readings in the en-
zyme-linked immunosorbent assay (ELISA). It would be
useful for interpreting this study to more clearly understand
whether these are the same immunized animals as in Ref. 9
of the Hamburger et al. paper or different animals. If same,
then which of the four animals immunized with Synvisc in
that study are in these three sera ‘‘pools’’? Figure 1 de-
scribes antibody levels from rabbit sera following immuniza-
tion with Synvisc, Hyalgan, and a Crude Roster Comb
(CRC) preparation. Data are shown for only one animal im-
munized with CRC and Hyalgan. As is seen in Fig. 1 with
the Synvisc immunized animals large variations can occur
in this model. The large variation between the low, medium,
and high titer pool animals upon immunization with the8
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the same amount of material, drawing conclusions from
a single animal highly questionable scientiﬁcally. (2) Hyal-
uronidase was used to digest the HA in the CRC, but the
hyaluronidase source and type, and conditions of the enzy-
matic
digestion are not provided. Additionally, there is no indica-
tion of where the hyaluronidase protein or possible contam-
inates from the enzyme preparation migrate in the sodium
dodecyl sulphate-polyarcylamide gel electrophoresis (SDS-
PAGE) gel. This information would provide a better under-
standing of the source and reactivity of the bands in the
SDS-PAGE gel and allows the creation of the CRC in order
to replicate the experiment. (3) Staining in the Western blot
of CRC with anti-hylan G-F 20 is very faint in the 6e8 kDa
region as compared to the strong reactivity observed with
CRC antisera and does not appear to correlate with the
ELISA reactivity. The authors say that they used the ‘‘high’’
titer pool Synvisc G-F 20 antisera to react in the CRC
Western blot. According to Fig. 1 for a 1:500 dilution this
group had an OD value of about 2.5 compared to about
1.75 for the CRC antisera. Following the arguments of Ham-
burger et al., the concentration and/or immunogenicity of
the putative antigenic protein(s) would be greater in the
commercial preparation than in the CRC preparation. Thus,
one would expect the reactivity of the hylan G-F 20 antisera
to be similar, if not greater, to that observed with the anti-
CRC sera. Yet as shown in Fig. 2 this is not the case.
The apparent reactivity with anti-hylan G-F 20 is not con-
vincing, and is certainly not scientiﬁcally sufﬁcient for con-
cluding that ‘‘The results of this preclinical study conﬁrm
the presence of a speciﬁc immunogenic protein species.’’.
A more direct and scientiﬁcally convincing study would have
examined CRC and hylan G-F 20 antisera reactivity with
a hylan G-F 20 Western blot to identify potentially immuno-
genic proteins in the product directly. Even using this meth-
od, the exact protein or polypeptide epitope(s), their
concentration(s), and the exact way they are covalently
bound to the HA backbone will vary from lot to lot of com-
mercial product. This limits the ability of the authors to gen-
eralize their conclusions.
It is not credible for one to imply that no immunogenic po-
tential exists for a given implantable material when that ma-
terial contains even low amounts of foreign protein. It isequally not credible to represent that a particular visco-
supplement preparation has a unique safety proﬁle when
the available public information provided by the products’
package inserts and the FDA MAUDE database indicates
otherwise. It seems clear that the occurrence of reactions
to viscosupplements is likely rare, and not unique to any
given product. The biology of such reactions is still un-
known, and the Hamburger et al. study does not advance
our understanding of their etiology. Ultimately, the safety
and efﬁcacy of viscosupplements are best understood from
well designed and executed scientiﬁc experiments, and
from the results of well controlled clinical trials as repre-
sented on FDA approved product labeling.
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